Merck announced yesterday that the FDA has approved Keytruda in combination with carboplatin and paclitaxel, followed by Keytruda alone, to treat adult patients with advanced or recurrent endometrial carcinoma.

This approval is based on the results of a ph. III trial, which demonstrated a significant reduction in the risk of disease progression or death.

This trial is the first to statistically evaluate anti-PD-1 immunotherapy combined with chemotherapy in patients with pMMR and dMMR tumors.

This approval is important, as endometrial cancer is on the rise and is expected to surpass ovarian cancer deaths by 2024, the company points out.

Copyright (c) 2024 CercleFinance.com. All rights reserved.